Payment overview · 2025
General Payments
$1,816.35
100 reported records · 17 companies
Healthcare provider profile · identity verified
Danielle Zachar, DO
Allopathic & Osteopathic Physicians|Family Medicine · BENTLEYVILLE, PA · NPI 1639602832
Verified facts
What the public records show
CMS Open Payments records show Danielle Zachar, DO received $1,816.35 in general payments during 2025 across 100 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $337.22 | 18.6% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $321.42 | 17.7% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $287.98 | 15.8% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $188.95 | 10.4% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.13 | 8.8% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.37 | 5.6% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.87 | 4.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.64 | 3.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.46 | 3.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.89 | 2.4% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $40.28 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.71 | 2.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.17 | 1.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.56 | 1.1% | 1 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $18.18 | 1.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.07 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.45 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,816.35 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $272.96 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $219.56 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $188.95 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $172.23 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $161.76 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $160.13 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $148.56 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.73 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $120.40 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $108.73 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $106.98 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.37 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.40 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $88.69 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $75.87 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $61.64 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.46 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.89 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $40.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 73 |
| Lisinopril | Lisinopril | 286 | 72 |
| Gabapentin | Gabapentin | 263 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 65 |
| Losartan Potassium | Losartan Potassium | 208 | 48 |
| Simvastatin | Simvastatin | 199 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 63 |
| Metformin Hcl | Metformin Hcl | 155 | 38 |
| Furosemide | Furosemide | 144 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 30 |
| Montelukast Sodium | Montelukast Sodium | 122 | 38 |
| Omeprazole | Omeprazole | 122 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 34 |
| Carvedilol | Carvedilol | 111 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 33 |
| Buspirone Hcl | Buspirone Hcl | 95 | 18 |
| Sertraline Hcl | Sertraline Hcl | 94 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 22 |
| Mounjaro | Tirzepatide | 89 | 17 |
| Ibuprofen | Ibuprofen | 86 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 21 |
| Bupropion Xl | Bupropion Hcl | 74 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 14 |
| Celecoxib | Celecoxib | 71 | 18 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Eliquis | Apixaban | 70 | 20 |
| Famotidine | Famotidine | 70 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 20 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 12 |
| Ezetimibe | Ezetimibe | 63 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 11 |
| Methylprednisolone | Methylprednisolone | 58 | 46 |
| Trulicity | Dulaglutide | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Jardiance | Empagliflozin | 53 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Amoxicillin | Amoxicillin | 47 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 14 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Ozempic | Semaglutide | 46 | 13 |
| Prednisone | Prednisone | 46 | 39 |
| Atenolol | Atenolol | 45 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 14 |
| Loperamide | Loperamide Hcl | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 15 |
| Mupirocin | Mupirocin | 36 | 28 |
| Ondansetron Odt | Ondansetron | 36 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 13 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Finasteride | Finasteride | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Etodolac | Etodolac | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nystatin | Nystatin | 16 | 15 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,816.35 · 100 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAMZYOS, Cologuard Collection Kit, ELIQUIS, FARXIGA, FEMLYV, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INTRAROSA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error